Reuters logo
BRIEF-Merck says phase 3 study with Letermovir meets its primary endpoint
2016年10月19日 / 上午11点22分 / 1 年前

BRIEF-Merck says phase 3 study with Letermovir meets its primary endpoint

Oct 19 (Reuters) - Merck & Co Inc :

* Merck announces pivotal phase 3 study of letermovir, an investigational antiviral medicine for prevention of cytomegalovirus (cmv) infection in high-risk bone marrow transplant patients, met primary endpoint

* Merck announces pivotal phase 3 study of letermovir, an investigational antiviral medicine for prevention of cytomegalovirus (cmv) infection in high-risk bone marrow transplant patients, met primary endpoint

* Merck & co inc - phase 3 study with letermovir met its primary endpoint Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below